ArticleOncoTargets and therapy2016

Pemetrexed had significantly better clinical efficacy in patients with stage IV lung adenocarcinoma with susceptible EGFR mutations receiving platinum-based chemotherapy after developing resistance to the first-line gefitinib treatment.

Chih-Jen Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.